Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B raises $17.5mm for VeraLight

Executive Summary

VeraLight (medical devices for diabetes screening) brought in $17.5mm from its Series B financing round led by first-time investor Psilos Group with participation from other new backer CMEA Ventures and returning shareholders vSpring Capital, Wasatch Venture Fund, Dow Chemical, and the Southern Ute Growth Fund. One member each from Psilos and CMEA will each take a seat on the company's board. VeraLight will use the proceeds to finish developing and eventually commercialize its Scout diabetes screening system.
Deal Industry
  • In Vitro Diagnostics
  • Medical Devices
  • Medical Devices
    • Diagnostic Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies